Endocrinology Calculators

Interprets HbA1c in mmol/mol (IFCC). Classifies diabetes control and identifies diagnostic thresholds.

Classifies diabetic ketoacidosis severity using pH, bicarbonate, and blood ketone levels.

Converts corticosteroid doses to prednisolone equivalent. Useful for switching steroids or assessing adrenal suppression risk.

Corrects serum sodium for the dilutional effect of hyperglycaemia to reveal true sodium status.

Combined BMI and waist circumference assessment for metabolic risk classification.

Estimates total daily dose (TDD) of insulin for new insulin starts. 50% basal, 50% bolus split.

Interprets TSH and free T4 pattern to classify thyroid function status.

Finnish Diabetes Risk Score for predicting 10-year risk of developing type 2 diabetes.

Homeostatic Model Assessment of Insulin Resistance. HOMA-IR = (Fasting Glucose × Fasting Insulin) / 22.5.

IDF 2006 criteria for metabolic syndrome. Central obesity is required plus ≥2 of 4 additional criteria.

Rotterdam 2003 diagnostic criteria for Polycystic Ovary Syndrome. Requires 2 of 3 criteria after exclusion of other aetiologies.

Simplified UKPDS-based cardiovascular risk factors guide in T2DM. Score used to prioritise treatment intensity.

Scoring system for diagnosing thyroid storm (thyrotoxic crisis) and guiding treatment urgency. Score ≥ 45 is diagnostic of thyroid storm.

Calculates Ideal Body Weight (Devine formula) and Adjusted Body Weight for use in drug dosing, ventilator settings, and nutrition.

Clinical and biochemical assessment for primary (Addison's disease) and secondary adrenal insufficiency, including adrenal crisis risk.

10-item validated risk assessment tool for identifying Australians at high risk of developing type 2 diabetes within 5 years. Also used internationally. Score ≥12 = high risk. Equivalent to FINDRISC adapted for Australian population.

5-stage clinical staging system for obesity that incorporates comorbidities, functional limitations, and wellbeing — beyond BMI alone. Guides treatment intensity. Stage 0 = no complications; Stage 4 = end-stage complications.

Simple anthropometric formula estimating body fat percentage using height and waist circumference. More accurate than BMI for predicting body fat. Males: RFM = 64 − (20 × height/waist). Females: RFM = 76 − (20 × height/waist).

8-item validated questionnaire for screening pre-diabetes and undiagnosed type 2 diabetes in Canadian adults ≥40 years. Score ≥21 = high risk. Similar to FINDRISC/AUSDRISK but adapted for Canadian population including Aboriginal and South Asian groups.

Calculates glucose infusion rate in mg/kg/min from IV infusion parameters. Critical for neonatal and paediatric care, and for insulin infusion management in adults. Confirms adequate glucose delivery.

Estimates basal/resting energy expenditure (REE/BEE) in kcal/day using age, weight, height, and sex. Total Daily Energy Expenditure (TDEE) = REE × activity factor. Widely used for nutrition planning in clinical and outpatient settings.

Estimates how much 1 unit of rapid-acting insulin will lower blood glucose. Calculated using 'Rule of 1700' (mmol/L) or 'Rule of 1800' (mg/dL) divided by Total Daily Dose (TDD). Used for correction bolus dosing in type 1 and type 2 diabetes.

Estimates starting levothyroxine dose for hypothyroidism based on lean body weight and severity. Target dose for primary hypothyroidism: 1.6 mcg/kg/day. Lower in elderly (0.8–1.0 mcg/kg) and cardiac disease (12.5–25 mcg start).

Fasting C-peptide to fasting glucose ratio helps distinguish type 1 from type 2 diabetes and assesses residual beta-cell function. Low ratio suggests type 1 or insulin deficiency; high ratio suggests type 2 or insulin resistance.

Quantifies likelihood of thyroid storm (thyrotoxic crisis). Score >= 45 = thyroid storm; 25-44 = impending storm.

Identifies diabetic patients at risk of DKA or HHS during illness. Guides sick day rule application and hospital admission.

Estimates clinical likelihood of Cushing syndrome to guide biochemical testing (24h UFC, LNSC, LDDST).

Structured scoring tool for acromegaly diagnosis and disease activity assessment using clinical signs, IGF-1, GH, and complications.

Identifies patients at risk of adrenal crisis (adrenocortical insufficiency during physiological stress). Guides sick day rule for hydrocortisone.

Assesses clinical probability of pheochromocytoma/paraganglioma. Often called the "10% tumor" for its prevalence in syndromic contexts.

Classifies hypoglycaemia severity to guide acute management (rule of 15/20) and prevention strategy.

Systematically interprets TSH + free T4 patterns to identify hypothyroid, hyperthyroid, subclinical, and central thyroid disease. Guides management decisions.